Literature DB >> 19800878

Blocking platelet/endothelial cell adhesion molecule 1 (PECAM) inhibits disease progression and prevents joint erosion in established collagen antibody-induced arthritis.

Bidisha Dasgupta1, Tina Chew, Alana deRoche, William A Muller.   

Abstract

Collagen antibody-induced arthritis is a robust murine model of arthritis that histologically recapitulates the inflammatory characteristics of rheumatoid arthritis including pannus formation and destruction of articular cartilage and bone. PECAM is a molecule expressed by both leukocytes and endothelial cells that has been shown to play a major role in the extravasation of leukocytes into sites of inflammation. Genetic deletion of many molecules will blunt the onset and progression of arthritis in murine models, as will administration of various anti-inflammatory therapies given prior to the onset of disease. However, patients seek medical attention when symptomatic, which means that the disease is well established. We investigated whether blocking PECAM interactions would inhibit progression of established disease in the collagen antibody-induced arthritis model. We report that treatment of symptomatic mice with a PECAM-Fc chimera significantly reduced inflammation and virtually eliminated cartilage and bone destruction. The results suggest that therapies that block PECAM function may be beneficial in the treatment of established arthritis. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800878      PMCID: PMC2815035          DOI: 10.1016/j.yexmp.2009.09.013

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  32 in total

1.  A new mouse model of rheumatoid arthritis: organ-specific disease provoked by systemic autoimmunity.

Authors:  V Kouskoff; A S Korganow; V Duchatelle; C Degott; C Benoist; D Mathis
Journal:  Ryumachi       Date:  1997-04

Review 2.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  M Feldmann; R N Maini
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

3.  Platelet endothelial cell adhesion molecule deficiency or blockade significantly reduces leukocyte emigration in a majority of mouse strains.

Authors:  Alan R Schenkel; Tina W Chew; William A Muller
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

4.  Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.

Authors:  Emily K Reinke; Jangeun Lee; Alla Zozulya; Jozsef Karman; William A Muller; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Neuroimmunol       Date:  2007-04-27       Impact factor: 3.478

Review 5.  The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo.

Authors:  W A Muller
Journal:  J Leukoc Biol       Date:  1995-04       Impact factor: 4.962

6.  Acceleration of the onset of collagen-induced arthritis by a deficiency of platelet endothelial cell adhesion molecule 1.

Authors:  Yoshifumi Tada; Syuichi Koarada; Fumitaka Morito; Osamu Ushiyama; Yoshio Haruta; Futoshi Kanegae; Akihide Ohta; Alexandra Ho; Tak W Mak; Kohei Nagasawa
Journal:  Arthritis Rheum       Date:  2003-11

7.  Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo.

Authors:  A A Vaporciyan; H M DeLisser; H C Yan; I I Mendiguren; S R Thom; M L Jones; P A Ward; S M Albelda
Journal:  Science       Date:  1993-12-03       Impact factor: 47.728

8.  Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo.

Authors:  F Liao; J Ali; T Greene; W A Muller
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

9.  Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1.

Authors:  F Liao; H K Huynh; A Eiroa; T Greene; E Polizzi; W A Muller
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo.

Authors:  S Bogen; J Pak; M Garifallou; X Deng; W A Muller
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  8 in total

1.  NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Johannes T Wessels; Agnes Schröder; Michael J May; Dietmar Vestweber; Jochen Zwerina; Klaus Warnatz; Falk Nimmerjahn; Georg Schett; Stefan Dübel; Reinhard Edmund Voll
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

Review 2.  Monocyte trafficking across the vessel wall.

Authors:  Teresa Gerhardt; Klaus Ley
Journal:  Cardiovasc Res       Date:  2015-05-19       Impact factor: 10.787

3.  How endothelial cells regulate transmigration of leukocytes in the inflammatory response.

Authors:  William A Muller
Journal:  Am J Pathol       Date:  2014-04       Impact factor: 4.307

Review 4.  PECAM-1: conflicts of interest in inflammation.

Authors:  Jamie R Privratsky; Debra K Newman; Peter J Newman
Journal:  Life Sci       Date:  2010-06-10       Impact factor: 5.037

5.  Network pharmacology combined with GEO database identifying the mechanisms and molecular targets of Polygoni Cuspidati Rhizoma on Peri-implants.

Authors:  Chao Shan; Xiaowei Ji; Zeyu Wu; Jin Zhao
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

6.  PECAM-1 gene polymorphisms and soluble PECAM-1 level in rheumatoid arthritis and systemic lupus erythematosus patients: any link with clinical atherosclerotic events?

Authors:  Omer Nuri Pamuk; Hilmi Tozkir; Mehmet Sevki Uyanik; Hakan Gurkan; Fatih Saritas; Julide Duymaz; Salim Donmez; Metin Yazar; Gulsum Emel Pamuk
Journal:  Clin Rheumatol       Date:  2014-09-10       Impact factor: 2.980

7.  TRPC6 is the endothelial calcium channel that regulates leukocyte transendothelial migration during the inflammatory response.

Authors:  Evan W Weber; Fei Han; Mohammad Tauseef; Lutz Birnbaumer; Dolly Mehta; William A Muller
Journal:  J Exp Med       Date:  2015-09-21       Impact factor: 14.307

8.  Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway.

Authors:  Loredana Bury; Emanuela Falcinelli; Anna Maria Mezzasoma; Giuseppe Guglielmini; Stefania Momi; Paolo Gresele
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.